Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...

Mayo Clinic researchers have identified a drug-and-supplement combination therapy that is capable of reducing the harmful effects of senescent cells—also known as "zombie cells"—in diabetic kidney ...

Preliminary safety data from a French registry on combination therapy in immune-mediated inflammatory diseases (IMIDs) show a concerning rate of serious infections and illustrate the need for ...

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes and CKD had a greater UACR reduction with finerenone plus empagliflozin vs. either ...

Mortality from invasive aspergillosis remains unacceptably high, and the currently recommended treatment of triazoles is further challenged by rising resistance to these first-line agents. A previous ...

A combination of brexpiprazole (Rexulti) and sertraline improved post-traumatic stress disorder (PTSD) symptoms more than sertraline alone, a phase III trial found. The primary endpoint was the change ...